These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 25817223)
1. Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications. Yang CY; Chang ZF; Chau YP; Chen A; Yang WC; Yang AH; Lee OK Nephrol Dial Transplant; 2015 Aug; 30(8):1356-63. PubMed ID: 25817223 [TBL] [Abstract][Full Text] [Related]
2. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis. Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190 [TBL] [Abstract][Full Text] [Related]
3. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Drechsler C; Evenepoel P; Vervloet MG; Wanner C; Ketteler M; Marx N; Floege J; Dekker FW; Brandenburg VM; Nephrol Dial Transplant; 2015 Feb; 30(2):288-93. PubMed ID: 25248363 [TBL] [Abstract][Full Text] [Related]
4. Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients. Lee YT; Ng HY; Chiu TT; Li LC; Pei SN; Kuo WH; Lee CT Clin Chim Acta; 2016 Jan; 452():38-43. PubMed ID: 26522655 [TBL] [Abstract][Full Text] [Related]
5. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Viaene L; Behets GJ; Claes K; Meijers B; Blocki F; Brandenburg V; Evenepoel P; D'Haese PC Nephrol Dial Transplant; 2013 Dec; 28(12):3024-30. PubMed ID: 23605174 [TBL] [Abstract][Full Text] [Related]
6. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Hampson G; Edwards S; Conroy S; Blake GM; Fogelman I; Frost ML Bone; 2013 Sep; 56(1):42-7. PubMed ID: 23702386 [TBL] [Abstract][Full Text] [Related]
7. The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus. Gaudio A; Privitera F; Pulvirenti I; Canzonieri E; Rapisarda R; Fiore CE Diab Vasc Dis Res; 2014 Jan; 11(1):48-52. PubMed ID: 24227537 [TBL] [Abstract][Full Text] [Related]
8. Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients? Pelletier S; Confavreux CB; Haesebaert J; Guebre-Egziabher F; Bacchetta J; Carlier MC; Chardon L; Laville M; Chapurlat R; London GM; Lafage-Proust MH; Fouque D Osteoporos Int; 2015 Aug; 26(8):2165-74. PubMed ID: 25910747 [TBL] [Abstract][Full Text] [Related]
11. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study. Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108 [TBL] [Abstract][Full Text] [Related]
12. Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases. Kawazoe M; Kaneko K; Shikano K; Kusunoki N; Nanki T; Kawai S Clin Rheumatol; 2018 Aug; 37(8):2169-2178. PubMed ID: 28551822 [TBL] [Abstract][Full Text] [Related]
13. Correlation between sclerostin and Dickkopf-1 with aortic arterial stiffness in patients with type 2 diabetes: A prospective, cross-sectional study. Yang HY; Wu DA; Chen MC; Hsu BG Diab Vasc Dis Res; 2019 May; 16(3):281-288. PubMed ID: 30547685 [TBL] [Abstract][Full Text] [Related]
14. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659 [TBL] [Abstract][Full Text] [Related]
15. Sclerostin and Dickkopf-1 in renal osteodystrophy. Cejka D; Herberth J; Branscum AJ; Fardo DW; Monier-Faugere MC; Diarra D; Haas M; Malluche HH Clin J Am Soc Nephrol; 2011 Apr; 6(4):877-82. PubMed ID: 21164019 [TBL] [Abstract][Full Text] [Related]
16. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD. Behets GJ; Viaene L; Meijers B; Blocki F; Brandenburg VM; Verhulst A; D'Haese PC; Evenepoel P PLoS One; 2017; 12(5):e0176411. PubMed ID: 28493902 [TBL] [Abstract][Full Text] [Related]
17. High Serum Sclerostin Levels Are Associated with a Better Outcome in Haemodialysis Patients. Jean G; Chazot C; Bresson E; Zaoui E; Cavalier E Nephron; 2016; 132(3):181-90. PubMed ID: 26890570 [TBL] [Abstract][Full Text] [Related]
18. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Thambiah S; Roplekar R; Manghat P; Fogelman I; Fraser WD; Goldsmith D; Hampson G Calcif Tissue Int; 2012 Jun; 90(6):473-80. PubMed ID: 22527202 [TBL] [Abstract][Full Text] [Related]
19. Circulating Levels of Dickkopf-Related Protein 1 Decrease as Measured GFR Declines and Are Associated with PTH Levels. Forster CM; White CA; Turner ME; Norman PA; Ward EC; Hopman WM; Adams MA; Holden RM Am J Nephrol; 2020; 51(11):871-880. PubMed ID: 33238271 [TBL] [Abstract][Full Text] [Related]
20. Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine. Kashii M; Matuso Y; Sugiura T; Fujimori T; Nagamoto Y; Makino T; Kaito T; Ebina K; Iwasaki M; Yoshikawa H J Bone Miner Metab; 2016 May; 34(3):315-24. PubMed ID: 26040409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]